       Document 0147
 DOCN  M9630147
 TI    In-vitro and intracellular activity of rifabutin on drug-susceptible and
       multiple drug-resistant (MDR) tubercle bacilli.
 DT    9603
 AU    Luna-Herrera J; Reddy MV; Gangadharam PR; Department of Medicine,
       University of Illinois at Chicago 60612,; USA.
 SO    J Antimicrob Chemother. 1995 Aug;36(2):355-63. Unique Identifier :
       AIDSLINE MED/96052020
 AB    Rifabutin, a spiropiperidyl derivative of rifampicin, is approved for
       the prophylaxis of Mycobacterium avium infections in AIDS patients in
       the US, and for the treatment of M. avium infections, tuberculosis and
       multiple drug resistant tuberculosis in many countries. In the present
       study, rifabutin was compared with rifampicin for its activity against
       drug susceptible and multi-drug resistant tubercle bacilli by several
       in-vitro and macrophage studies. Rifabutin exhibited similar or greater
       in-vitro activity than rifampicin as judged by the minimal inhibitory
       concentration (MIC), minimal bactericidal concentration (MBC) and
       MBC/MIC ratios, as well as continuous exposure and post-antibiotic
       effect studies. Rifabutin has been shown to be active against some
       multiple drug resistant strains which were resistant to rifampicin. In
       macrophage studies with continuous exposure to the drug or when the drug
       had been removed after 24 h, rifabutin also demonstrated high activity
       which was better than RMP against intracellular tubercle bacilli. This
       long-acting intracellular anti-mycobacterial activity may explain, in
       part, the clinical efficacy of rifabutin.
 DE    Antibiotics, Antitubercular/*PHARMACOLOGY  *Drug Resistance, Multiple
       Human  In Vitro  Macrophages/MICROBIOLOGY  Microbial Sensitivity Tests
       Mycobacterium tuberculosis/*DRUG EFFECTS  Rifabutin/*PHARMACOLOGY
       Rifampin/PHARMACOLOGY  Support, Non-U.S. Gov't  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

